Markets:

Overview

News

Currencies

International

Treasuries

Alkermes plc - Ordinary Shares (NQ:ALKS)

28.61 +0.42 (+1.49%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alkermes plc - Ordinary Shares

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Saint Warren ↗

June 28, 2021

Today the WTI oil price rose further up over 1%.

Via Talk Markets

Alkermes Announces Former Professional Baseball Player, CC Sabathia, as Spokesperson for Alcohol Dependence Awareness Campaign

June 24, 2021

SOURCE: Alkermes

Via 3BL Media

Forget Biogen: These 2 Under-the-Radar Biotechs Are Also Celebrating Breakthroughs ↗

June 13, 2021

Biogen isn't the only company whose shares should benefit from a breakthrough drug.

Via The Motley Fool

The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts ↗

June 11, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 10) Alexion Pharmaceuticals,...

Via Benzinga

Alkermes Celebrates Alcoholics Anonymous Founders Day

June 10, 2021

SOURCE: Alkermes

Via 3BL Media

The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda ↗

June 15, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 14) Alkermes plc (NASDAQ: ALKS...

Via Benzinga

The Daily Biotech Pulse: US To Procure 500M Pfizer-BioNTech Vaccine Doses For Donation, Verona Out-Licenses COPD Drug, Nautilus Lists Through SPAC Deal ↗

June 10, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 9) Aethlon Medical, Inc. (...

Via Benzinga

The Boston Club Recognizes Alkermes plc and Blue Cross Blue Shield of Massachusetts With First President's Award

May 17, 2021

SOURCE: Alkermes

Via 3BL Media

Wednesday News And Catch-Up ↗

June 09, 2021

Today the US market resumed its attempt to hit a new record for the S&P 500 and Nasdaq, but not the DJIA.

Via Talk Markets

Topics Stocks

The Daily Biotech Pulse: Lyra Gains On Positive Regulatory Outcome, FDA Nod For Pfizer's Prevnar Vaccine, Merck Inks COVID-19 Treatment Supply Deal With US ↗

June 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 8) Agios Pharmaceuticals, Inc...

Via Benzinga

Juvenile Investing Mob ↗

June 08, 2021

Tech stocks did well in Europe but not in the US. The data are unconvincing.

Via Talk Markets

The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex ↗

June 08, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 7) Agios Pharmaceuticals, Inc...

Via Benzinga

Alkermes: Diversity Strengthens Our Culture

June 07, 2021

SOURCE: Alkermes

Via 3BL Media

A Better Switch ↗

June 04, 2021

Today the US market decided to rise because President Biden is pondering not linking his infrastructure project to a corporate tax increase.

Via Talk Markets

The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck ↗

June 07, 2021

Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical Oncology meeting got underway during the week,...

Via Benzinga

"I'm Incredibly Proud to Work at a Company Whose Mission Is To Help Families Like Mine"

June 02, 2021

SOURCE: Alkermes

Via 3BL Media

Alkermes Shares Move Higher On FDA Approval Of Schizophrenia, Bipolar Med ↗

June 01, 2021

The FDA has approved Alkermes plc's (NASDAQ: ALKS) Lybalvi, a once-daily, oral atypical antipsychotic composed of olanzapine, an established antipsychotic...

Via Benzinga

The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes ↗

May 31, 2021

After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-...

Via Benzinga

Alkermes Inspiration Grants® 2021 Applications Are Now Open

May 24, 2021

SOURCE: Alkermes

Via 3BL Media

Alkermes Celebrates Mental Health Month

May 19, 2021

SOURCE: Alkermes

Via 3BL Media

Alkermes Announces 2021 Alkermes Inspiration Grants® Program to Support Innovative Programs Focused on People Affected by Addiction, Serious Mental Illness or Cancer

May 13, 2021

SOURCE: Alkermes

Via 3BL Media

Why Shares of Alkermes Rose 18% Last Month ↗

May 07, 2021

An agreement with an activist investor capped a busy month.

Via The Motley Fool

Want to Make Money in Biotech? Do This First ↗

May 07, 2021

Keeping track of upcoming events is important.

Via The Motley Fool

Topics Regulatory Compliance

Alkermes to Showcase Data From Psychiatry Portfolio at Upcoming Scientific Conferences Throughout Mental Health Awareness Month

May 04, 2021

SOURCE: Alkermes

Via 3BL Media

Topics Regulatory Compliance

The Daily Biotech Pulse: Hyperphosphatemia Drug Regulatory Review Extended, Phathom Pharma Data Readout, 2 IPOs ↗

April 30, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 29) AtriCure, Inc. (NASDAQ:...

Via Benzinga

Alkermes PLC (ALKS) Q1 2021 Earnings Call Transcript ↗

April 29, 2021

ALKS earnings call for the period ending March 31, 2021.

Via The Motley Fool

Topics Earnings

Alkermes Launches New Disease State Website to Offer Education About Alcohol Dependence

April 29, 2021

SOURCE: Alkermes

Via 3BL Media

Alkermes: Q1 Earnings Insights ↗

April 28, 2021

Shares of Alkermes (NASDAQ:ALKS) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share increased 1000.00% year over year to $0.11,...

Via Benzinga

The Daily Biotech Pulse: FDA Rejection For Protalix, Amgen Q1 Trail Estimates, Pfizer Goes Shopping ↗

April 28, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 27) Aldeyra Therapeutics, Inc...

Via Benzinga

Alkermes Launches Mid-Stage Melanoma Study Of Nemvaleukin As Monotherapy ↗

April 27, 2021

Alkermes plc (NASDAQ: ALKS) has initiated a Phase 2 trial, ARTISTRY-6, evaluating nemvaleukin alfa (nemvaleukin) monotherapy in patients with melanoma...

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Alkermes plc - Ordinary Shares (NQ:ALKS)

All News about Alkermes plc - Ordinary Shares

Starting at $3.75/week.

Subscribe Today